Rep. Gilbert Ray Cisneros, Jr. Buys Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares

10 Apr 2026, 17:08 by Doug Wharley · The Cerbat Gem

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 3rd.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Crinetics Pharmaceuticals Stock Performance

NASDAQ CRNX traded down $0.19 on Friday, reaching $39.44. The company had a trading volume of 760,521 shares, compared to its average volume of 1,264,703. The firm has a market capitalization of $4.13 billion, a price-to-earnings ratio of -7.98 and a beta of 0.30. Crinetics Pharmaceuticals, Inc. has a 1-year low of $25.83 and a 1-year high of $57.99. The company’s fifty day moving average is $40.56 and its 200-day moving average is $44.11.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($1.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.08. The firm had revenue of $6.16 million during the quarter, compared to analyst estimates of $4.32 million. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 41.46%. The company’s revenue for the quarter was up NaN% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.88) EPS. On average, research analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current year.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

A number of large investors have recently modified their holdings of CRNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Crinetics Pharmaceuticals by 11.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company’s stock valued at $1,995,000 after purchasing an additional 6,148 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Crinetics Pharmaceuticals by 6.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company’s stock valued at $11,658,000 after purchasing an additional 22,305 shares during the last quarter. Strs Ohio acquired a new stake in Crinetics Pharmaceuticals in the 1st quarter valued at about $124,000. JPMorgan Chase & Co. lifted its stake in Crinetics Pharmaceuticals by 25.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 331,957 shares of the company’s stock valued at $9,547,000 after purchasing an additional 66,462 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in Crinetics Pharmaceuticals by 10.0% in the 2nd quarter. Legal & General Group Plc now owns 97,532 shares of the company’s stock valued at $2,805,000 after purchasing an additional 8,905 shares during the last quarter. 98.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRNX has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research note on Wednesday, January 21st. Citizens Jmp reduced their price objective on shares of Crinetics Pharmaceuticals from $105.00 to $96.00 and set a “market outperform” rating for the company in a research note on Monday, March 2nd. Lifesci Capital upgraded shares of Crinetics Pharmaceuticals to a “strong-buy” rating in a research note on Friday, February 13th. Morgan Stanley increased their price objective on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 price objective for the company in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Crinetics Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $76.63.

Check Out Our Latest Analysis on CRNX

Insiders Place Their Bets

In related news, CFO Tobin Schilke sold 6,713 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $39.67, for a total value of $266,304.71. Following the completion of the sale, the chief financial officer directly owned 78,121 shares in the company, valued at approximately $3,099,060.07. This trade represents a 7.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jeff E. Knight sold 85,163 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $40.10, for a total transaction of $3,415,036.30. Following the completion of the sale, the insider owned 105,289 shares of the company’s stock, valued at $4,222,088.90. This trade represents a 44.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 142,380 shares of company stock worth $5,569,475 in the last three months. Insiders own 4.60% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Crinetics Pharmaceuticals

(Get Free Report)

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.